Do analysts prefer MGNX or KVAC?

MacroGenics presently has a consensus price target of $5.50, indicating a potential upside of 34.97%. Given MacroGenics' stronger consensus rating and higher probable upside, equities analysts clearly believe MacroGenics is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29 Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, MGNX or KVAC?

Keen Vision Acquisition has lower revenue, but higher earnings than MacroGenics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MacroGenics $157.08M 1.65 -$74.62M -$1.10 N/A Keen Vision Acquisition N/A N/A N/A N/A N/A

Do analysts rate KVAC or RNAC?

Cartesian Therapeutics has a consensus target price of $32.60, indicating a potential upside of 277.75%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cartesian Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Which has preferable earnings and valuation, KVAC or RNAC?

Keen Vision Acquisition has higher earnings, but lower revenue than Cartesian Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Keen Vision Acquisition N/A N/A N/A N/A N/A Cartesian Therapeutics $2.80M 93.23 -$130.30M -$5.94 N/A

Is KVAC or RNAC more profitable?

Keen Vision Acquisition has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Company Net Margins Return on Equity Return on Assets Keen Vision Acquisition N/A N/A N/A Cartesian Therapeutics -8,550.65% N/A -29.84%

Do analysts rate ACIU or KVAC?

AC Immune presently has a consensus price target of $7.50, indicating a potential upside of 226.80%. Given AC Immune's stronger consensus rating and higher probable upside, equities analysts clearly believe AC Immune is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AC Immune 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, ACIU or KVAC?

Keen Vision Acquisition has lower revenue, but higher earnings than AC Immune. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AC Immune $4.31M 54.19 -$85.03M -$0.54 N/A Keen Vision Acquisition N/A N/A N/A N/A N/A

Do analysts recommend KVAC or CAPR?

Capricor Therapeutics has a consensus target price of $29.15, suggesting a potential upside of 658.13%. Given Capricor Therapeutics' higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Capricor Therapeutics 1 Sell rating(s) 10 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.91

Which has stronger earnings and valuation, KVAC or CAPR?

Keen Vision Acquisition has higher earnings, but lower revenue than Capricor Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Keen Vision Acquisition N/A N/A N/A N/A N/A Capricor Therapeutics $22.27M 10.00 -$105.04M -$2.32 N/A

Is KVAC or CAPR more profitable?

Keen Vision Acquisition's return on equity of 0.00% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Keen Vision Acquisition N/A N/A N/A Capricor Therapeutics N/A -59.27% -48.65%

Do analysts recommend TARA or KVAC?

Protara Therapeutics presently has a consensus price target of $26.25, indicating a potential upside of 537.91%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Protara Therapeutics is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protara Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, TARA or KVAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A Keen Vision Acquisition N/A N/A N/A N/A N/A

Is TARA or KVAC more profitable?

Keen Vision Acquisition's return on equity of 0.00% beat Protara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -38.70% -36.02% Keen Vision Acquisition N/A N/A N/A

Keen Vision Acquisition (KVAC) Competitors

$11.51 0.00 (0.00%)

As of 08/7/2026

Compare

KVAC vs. MGNX, RNAC, ACIU, CAPR, and TARA

Should you buy Keen Vision Acquisition stock or one of its competitors? MarketBeat compares Keen Vision Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Keen Vision Acquisition include MacroGenics (MGNX), Cartesian Therapeutics (RNAC), AC Immune (ACIU), Capricor Therapeutics (CAPR), and Protara Therapeutics (TARA). These companies are all part of the "biotechnology" industry.

How does Keen Vision Acquisition compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Keen Vision Acquisition has lower revenue, but higher earnings than MacroGenics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$157.08M	1.65	-$74.62M	-$1.10	N/A
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Keen Vision Acquisition has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Keen Vision Acquisition's return on equity of 0.00% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
Keen Vision Acquisition	N/A	N/A	N/A

MacroGenics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market.

In the previous week, MacroGenics had 2 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 2 mentions for MacroGenics and 0 mentions for Keen Vision Acquisition. MacroGenics' average media sentiment score of 0.34 beat Keen Vision Acquisition's score of 0.00 indicating that MacroGenics is being referred to more favorably in the media.

Company	Overall Sentiment
MacroGenics	Neutral
Keen Vision Acquisition	Neutral

MacroGenics presently has a consensus price target of $5.50, indicating a potential upside of 34.97%. Given MacroGenics' stronger consensus rating and higher probable upside, equities analysts clearly believe MacroGenics is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are held by institutional investors. 13.6% of MacroGenics shares are held by company insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

MacroGenics beats Keen Vision Acquisition on 8 of the 12 factors compared between the two stocks.

How does Keen Vision Acquisition compare to Cartesian Therapeutics?

Keen Vision Acquisition (NASDAQ:KVAC) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Keen Vision Acquisition has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%.

Company	Net Margins	Return on Equity	Return on Assets
Keen Vision Acquisition	N/A	N/A	N/A
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%

In the previous week, Cartesian Therapeutics had 10 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 10 mentions for Cartesian Therapeutics and 0 mentions for Keen Vision Acquisition. Cartesian Therapeutics' average media sentiment score of 0.66 beat Keen Vision Acquisition's score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Keen Vision Acquisition	Neutral
Cartesian Therapeutics	Positive

Keen Vision Acquisition has higher earnings, but lower revenue than Cartesian Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A
Cartesian Therapeutics	$2.80M	93.23	-$130.30M	-$5.94	N/A

51.7% of Keen Vision Acquisition shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 80.2% of Keen Vision Acquisition shares are owned by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Keen Vision Acquisition has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

Cartesian Therapeutics has a consensus target price of $32.60, indicating a potential upside of 277.75%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cartesian Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Cartesian Therapeutics beats Keen Vision Acquisition on 8 of the 11 factors compared between the two stocks.

How does Keen Vision Acquisition compare to AC Immune?

AC Immune (NASDAQ:ACIU) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

AC Immune has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Keen Vision Acquisition has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Keen Vision Acquisition's return on equity of 0.00% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-245.32%	-100.17%	-28.36%
Keen Vision Acquisition	N/A	N/A	N/A

AC Immune presently has a consensus price target of $7.50, indicating a potential upside of 226.80%. Given AC Immune's stronger consensus rating and higher probable upside, equities analysts clearly believe AC Immune is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, AC Immune had 9 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 9 mentions for AC Immune and 0 mentions for Keen Vision Acquisition. AC Immune's average media sentiment score of 1.00 beat Keen Vision Acquisition's score of 0.00 indicating that AC Immune is being referred to more favorably in the media.

Company	Overall Sentiment
AC Immune	Positive
Keen Vision Acquisition	Neutral

Keen Vision Acquisition has lower revenue, but higher earnings than AC Immune.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	54.19	-$85.03M	-$0.54	N/A
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

AC Immune beats Keen Vision Acquisition on 7 of the 12 factors compared between the two stocks.

How does Keen Vision Acquisition compare to Capricor Therapeutics?

Keen Vision Acquisition (NASDAQ:KVAC) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Capricor Therapeutics has a consensus target price of $29.15, suggesting a potential upside of 658.13%. Given Capricor Therapeutics' higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Capricor Therapeutics	1 Sell rating(s)	10 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.91

51.7% of Keen Vision Acquisition shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 80.2% of Keen Vision Acquisition shares are held by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Keen Vision Acquisition's return on equity of 0.00% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keen Vision Acquisition	N/A	N/A	N/A
Capricor Therapeutics	N/A	-59.27%	-48.65%

In the previous week, Capricor Therapeutics had 49 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 49 mentions for Capricor Therapeutics and 0 mentions for Keen Vision Acquisition. Keen Vision Acquisition's average media sentiment score of 0.00 beat Capricor Therapeutics' score of -0.06 indicating that Keen Vision Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
Keen Vision Acquisition	Neutral
Capricor Therapeutics	Neutral

Keen Vision Acquisition has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

Keen Vision Acquisition has higher earnings, but lower revenue than Capricor Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A
Capricor Therapeutics	$22.27M	10.00	-$105.04M	-$2.32	N/A

Summary

Keen Vision Acquisition beats Capricor Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Keen Vision Acquisition compare to Protara Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

In the previous week, Protara Therapeutics had 2 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 2 mentions for Protara Therapeutics and 0 mentions for Keen Vision Acquisition. Protara Therapeutics' average media sentiment score of 0.45 beat Keen Vision Acquisition's score of 0.00 indicating that Protara Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Protara Therapeutics	Neutral
Keen Vision Acquisition	Neutral

Protara Therapeutics presently has a consensus price target of $26.25, indicating a potential upside of 537.91%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Protara Therapeutics is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Protara Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Keen Vision Acquisition's return on equity of 0.00% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
Keen Vision Acquisition	N/A	N/A	N/A

Summary

Protara Therapeutics beats Keen Vision Acquisition on 6 of the 10 factors compared between the two stocks.

Get Keen Vision Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KVAC vs. The Competition

Export

Metric	Keen Vision Acquisition	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$63.37M	$3.71B	$7.04B	$12.94B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	N/A	9.08	269.98	24.78
Price / Sales	N/A	1,268.95	651.07	108.19
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	N/A	17.65	11.26	6.43
Net Income	N/A	-$13.25M	$3.45B	$347.27M
7 Day Performance	1.72%	5.21%	3.50%	2.54%
1 Month Performance	-6.26%	-1.91%	-0.64%	-1.00%
1 Year Performance	0.31%	60.70%	77.23%	23.33%

Keen Vision Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KVAC Keen Vision Acquisition	N/A	$11.51 flat	N/A	N/A	$63.37M	N/A	N/A	N/A
MGNX MacroGenics	2.4479 of 5 stars	$4.01 +2.8%	$5.50 +37.2%	+162.3%	$247.90M	$157.08M	N/A	430	Upcoming Earnings
RNAC Cartesian Therapeutics	2.7213 of 5 stars	$8.76 +4.9%	$32.60 +272.1%	-16.0%	$245.34M	$2.80M	N/A	64	Earnings Report Analyst Upgrade
ACIU AC Immune	2.6648 of 5 stars	$2.32 +1.3%	$7.50 +223.3%	+10.3%	$233.06M	$4.31M	N/A	140	Positive News Earnings Report Gap Up
CAPR Capricor Therapeutics	2.6247 of 5 stars	$4.18 +6.4%	$29.15 +597.4%	-54.9%	$227.59M	$22.27M	N/A	101	Trending News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KVAC) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Keen Vision Acquisition (KVAC) Competitors

KVAC vs. MGNX, RNAC, ACIU, CAPR, and TARA

How does Keen Vision Acquisition compare to MacroGenics?

Summary

How does Keen Vision Acquisition compare to Cartesian Therapeutics?

Summary

How does Keen Vision Acquisition compare to AC Immune?

Summary

How does Keen Vision Acquisition compare to Capricor Therapeutics?

Summary

How does Keen Vision Acquisition compare to Protara Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KVAC vs. The Competition

Keen Vision Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Keen Vision Acquisition (KVAC) Competitors

KVAC vs. MGNX, RNAC, ACIU, CAPR, and TARA

How does Keen Vision Acquisition compare to MacroGenics?

Which has better valuation and earnings, MGNX or KVAC?

Is MGNX or KVAC more profitable?

Which has more risk and volatility, MGNX or KVAC?

Does the media refer more to MGNX or KVAC?

Do analysts prefer MGNX or KVAC?

Do insiders & institutionals believe in MGNX or KVAC?

Summary

How does Keen Vision Acquisition compare to Cartesian Therapeutics?

Is KVAC or RNAC more profitable?

Does the media prefer KVAC or RNAC?

Which has preferable earnings and valuation, KVAC or RNAC?

Do insiders and institutionals believe in KVAC or RNAC?

Which has more volatility & risk, KVAC or RNAC?

Do analysts rate KVAC or RNAC?

Summary

How does Keen Vision Acquisition compare to AC Immune?

Which has more risk and volatility, ACIU or KVAC?

Do institutionals & insiders have more ownership in ACIU or KVAC?

Is ACIU or KVAC more profitable?

Do analysts rate ACIU or KVAC?

Does the media refer more to ACIU or KVAC?

Which has better earnings & valuation, ACIU or KVAC?

Summary

How does Keen Vision Acquisition compare to Capricor Therapeutics?

Do analysts recommend KVAC or CAPR?

Do insiders & institutionals hold more shares of KVAC or CAPR?

Is KVAC or CAPR more profitable?

Does the media prefer KVAC or CAPR?

Which has more volatility and risk, KVAC or CAPR?

Which has stronger earnings and valuation, KVAC or CAPR?

Summary

How does Keen Vision Acquisition compare to Protara Therapeutics?

Does the media refer more to TARA or KVAC?

Do analysts recommend TARA or KVAC?

Which has stronger valuation and earnings, TARA or KVAC?

Which has more volatility & risk, TARA or KVAC?

Do insiders and institutionals have more ownership in TARA or KVAC?

Is TARA or KVAC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KVAC vs. The Competition

Keen Vision Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools